New Multicenter Study Reveals Neurological Pupil index™ (NPi) as Predictor of Outcome and Mortality in Brain Injury Patients streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
E-Mail
Boston, MA (May 1, 2021) - A new study presented today at the AATS 101st Annual Meeting, found that the percentage of patients undergoing esophagectomy for cancer who suffer Venous Thromboembolism (VTE) post-operatively is much higher than previously reported, with as many as 24 percent suffering from Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE). Six-month mortality for patients with VTE was 17.6 percent compared to 2.1 percent for those without.
Venous Thromboembolism (VTE) is a common, potentially preventable post-operative complication leading to significant morbidity and mortality. Esophagectomy patients are amongst the highest risk groups for VTE due to disease burden, magnitude of surgery and high rate of perioperative morbidity. The study aimed to quantify the true incidence of VTE post esophagectomy, associated risk factors, and the impact of VTE on patients outcomes.
, Feb. 9, 2021 /PRNewswire/
Health Canada has approved Bactiguard s urinary catheter with temperature sensor for infection prevention through an Interim Order. The approval is driven by COVID-19, as Bactiguard s catheters can reduce the risk of secondary infections for critically ill patients. Many critically ill COVID-19 patients require a urinary catheter with integrated temperature monitoring. The ICU treatment period can be 14 days or more, which means patients will require an indwelling urinary catheter for a long period of time. Each day with a catheter increases the risk of acquiring catheter-associated urinary tract infection (CAUTI) and any secondary bacterial infection in these patients could worsen an already serious condition. With Bactiguard s catheter, this risk is significantly reduced , says Dr. Stefan Grass, Chief Medical Officer and deputy CEO at Bactiguard.